Kyung-Hee Kim1,2, Joon-Myung Kwon3,4, Tara Pereira5, Zachi I Attia2, Naveen L Pereira6,7. 1. Internal Medicine, Department of Cardiology, Incheon Sejong Hospital, Incheon, South Korea. 2. Department of Cardiovascular Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. 3. Department of Critical Care and Emergency Medicine, Incheon Sejong Hospital, Incheon, South Korea. 4. Medical Research Team, Medical AI, Co, Seoul, South Korea. 5. Artificial Intelligence Development, Center for Digital Health, Mayo Clinic, Rochester, USA. 6. Department of Cardiovascular Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. pereira.naveen@mayo.edu. 7. Department of Molecular Pharmacology and Therapeutics, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. pereira.naveen@mayo.edu.
Abstract
PURPOSE OF REVIEW: Artificial intelligence (AI) techniques have the potential to remarkably change the practice of cardiology in order to improve and optimize outcomes in heart failure and specifically cardiomyopathies, offering us novel tools to interpret data and make clinical decisions. The aim of this review is to describe the contemporary state of AI and digital health applied to cardiomyopathies as well as to define a potential pivotal role of its application by physicians in clinical practice. RECENT FINDINGS: Many studies have been undertaken in recent years on cardiomyopathy screening especially using AI-enhanced electrocardiography (ECG). Even with mild left ventricular (LV) dysfunction, AI-ECG screening for amyloidosis, hypertrophic cardiomyopathy, or dilated cardiomyopathy is now feasible. Introduction of AI-ECG in routine clinical care has resulted in higher detection of LV systolic dysfunction; however, clinical research on a broader scale with diverse populations is necessary and ongoing. In the area of cardiac-imaging, AI automatically assesses the thickness and characteristics of myocardium to differentiate cardiomyopathies, but research on its prognostic capability has yet to be conducted. AI is also being applied to cardiomyopathy genomics, especially to predict pathogenicity of variants and identify whether these variants are clinically actionable. While the implementation of AI in the diagnosis and treatment of cardiomyopathies is still in its infancy, an ever-growing clinical research strategy will ascertain the clinical utility of these AI tools to help improve diagnosis of and outcomes in cardiomyopathies. We also need to standardize the tools used to monitor the performance of AI-based systems which can then be used to expedite decision-making and rectify any hidden biases. Given its potential important role in clinical practice, healthcare providers need to familiarize themselves with the promise and limitations of this technology.
PURPOSE OF REVIEW: Artificial intelligence (AI) techniques have the potential to remarkably change the practice of cardiology in order to improve and optimize outcomes in heart failure and specifically cardiomyopathies, offering us novel tools to interpret data and make clinical decisions. The aim of this review is to describe the contemporary state of AI and digital health applied to cardiomyopathies as well as to define a potential pivotal role of its application by physicians in clinical practice. RECENT FINDINGS: Many studies have been undertaken in recent years on cardiomyopathy screening especially using AI-enhanced electrocardiography (ECG). Even with mild left ventricular (LV) dysfunction, AI-ECG screening for amyloidosis, hypertrophic cardiomyopathy, or dilated cardiomyopathy is now feasible. Introduction of AI-ECG in routine clinical care has resulted in higher detection of LV systolic dysfunction; however, clinical research on a broader scale with diverse populations is necessary and ongoing. In the area of cardiac-imaging, AI automatically assesses the thickness and characteristics of myocardium to differentiate cardiomyopathies, but research on its prognostic capability has yet to be conducted. AI is also being applied to cardiomyopathy genomics, especially to predict pathogenicity of variants and identify whether these variants are clinically actionable. While the implementation of AI in the diagnosis and treatment of cardiomyopathies is still in its infancy, an ever-growing clinical research strategy will ascertain the clinical utility of these AI tools to help improve diagnosis of and outcomes in cardiomyopathies. We also need to standardize the tools used to monitor the performance of AI-based systems which can then be used to expedite decision-making and rectify any hidden biases. Given its potential important role in clinical practice, healthcare providers need to familiarize themselves with the promise and limitations of this technology.
Authors: Marco Merlo; Antonio Cannatà; Marco Gobbo; Davide Stolfo; Perry M Elliott; Gianfranco Sinagra Journal: Eur J Heart Fail Date: 2017-12-22 Impact factor: 15.534
Authors: Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: Yigal M Pinto; Perry M Elliott; Eloisa Arbustini; Yehuda Adler; Aris Anastasakis; Michael Böhm; Denis Duboc; Juan Gimeno; Pascal de Groote; Massimo Imazio; Stephane Heymans; Karin Klingel; Michel Komajda; Giuseppe Limongelli; Ales Linhart; Jens Mogensen; James Moon; Petronella G Pieper; Petar M Seferovic; Stephan Schueler; Jose L Zamorano; Alida L P Caforio; Philippe Charron Journal: Eur Heart J Date: 2016-01-19 Impact factor: 29.983
Authors: Marta Gigli; Marco Merlo; Sharon L Graw; Giulia Barbati; Teisha J Rowland; Dobromir B Slavov; Davide Stolfo; Mary E Haywood; Matteo Dal Ferro; Alessandro Altinier; Federica Ramani; Francesca Brun; Andrea Cocciolo; Ilaria Puggia; Gaetano Morea; William J McKenna; Francisco G La Rosa; Matthew R G Taylor; Gianfranco Sinagra; Luisa Mestroni Journal: J Am Coll Cardiol Date: 2019-09-17 Impact factor: 24.094